SeptiBell: A novel first-in-class in vitro cellular immunoassay that identify bloodstream infection (progressing to sepsis) through the immune activity
Sepsis is a life-threatening condition caused by the body’s inflammatory response to an infection and is estimated to globally affect 30 million patients, 27 million hospital admissions, and inflict 6 million deaths per year. It is difficult to diagnose sepsis quickly and current diagnosis methods cannot quickly detect sepsis. Delayed treatment increases mortality, with the mortality rate increasing by approximately 10% for each hour without treatment. Hence, rapid identification of blood infection is crucial.
SeptiBell: A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection. This diagnostic device aids emergency physicians to make better clinical decisions and optimize sepsis management. The first rapid test that identifies bacterial infections in the blood through immune activity, activating the Sepsis Code.
Septic patients suffer from excess inflammation during 1-2 hours that leads to an immune-compromised phase; our approach explores how the immune system responds to an invading pathogen; in fact, detecting the specific immune response can determine infection 10x earlier than the bacterial identification techniques like blood culture and 50% more accurately than methods directly from blood.
SeptiBell is a technological solution focused on improving clinical practice, health management efficiency, and early decision making about the sepsis patient.